Anal carcinoma study

Electrocautery ablation therapy for anal intraepithelial carcinoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs032210649

Enrollment

Registered

2022-03-07

Start date

2022-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal carcinoma Ananl carcinoma, Human papillomavirus

Interventions

Electrocautery ablation therapy using Surgitron dual EMC for anal intraepithelial carcinoma

D000078703

ablation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Subjects who have given written consent to participate in the study. 2) person aged 20 years or older. 3) Patients with a diagnosis of anal intraepithelial carcinoma or neoplasia based on the results of histological findings

Exclusion criteria

Exclusion criteria: 1) Invasive cancer 2) Patients whom the principal investigator judges to be inappropriate for inclusion in the study. 3) pregnant or breastfeeding woman

Design outcomes

Primary

Measure	Time frame
Eradication rate of anal carcinoma after 6 months	—

Secondary

Measure	Time frame
Eradication rate of anal carcinoma after 3 months The rate of complication after ablation therapy	—

Contacts

Public ContactNaokatsu Ando

National Center for Global Health and Medicine

nandou@hosp.ncgm.go.jp+81-332027181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026